| Hauptseite > Publikationsdatenbank > Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia > print |
| 001 | 893884 | ||
| 005 | 20211018113109.0 | ||
| 024 | 7 | _ | |a 10.1111/bjh.17479 |2 doi |
| 024 | 7 | _ | |a 0007-1048 |2 ISSN |
| 024 | 7 | _ | |a 1365-2141 |2 ISSN |
| 024 | 7 | _ | |a 2128/28735 |2 Handle |
| 024 | 7 | _ | |a altmetric:105091596 |2 altmetric |
| 024 | 7 | _ | |a pmid:33931857 |2 pmid |
| 024 | 7 | _ | |a WOS:000646154400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2021-02896 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Taher, Ali T. |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia |
| 260 | _ | _ | |a Oxford [u.a.] |c 2021 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1633443945_22690 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Bitopertin is a small molecule selective inhibitor of glycine transporter 1 (GlyT1), initially developed to increase brain extracellular levels of glycine in the vicinity of neuronal N-methyl-D-aspartate receptors for the treatment of schizophrenia. GlyT1, the pharmacological target of bitopertin, is also present as a transmembrane transporter in erythroid cells1 and accounts for 50–55% of glycine uptake in human red blood cells (RBCs).2, 3 Erythroid GlyT1 inhibition by bitopertin leads to reduced intracellular glycine availability, interfering with the first step of haem synthesis, in which 5-aminolevulinate synthase catalyses the condensation reaction between glycine and succinyl-coenzyme A, forming 5-aminolevulinic acid.1 |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Viprakasit, Vip |b 1 |
| 700 | 1 | _ | |a Cappellini, Maria Domenica |0 0000-0001-8676-6864 |b 2 |
| 700 | 1 | _ | |a Kraus, Dominik |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Cech, Patrick |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Volz, Dietmar |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Winter, Erica |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Nave, Stephane |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Dukart, Juergen |0 P:(DE-Juel1)177772 |b 8 |
| 700 | 1 | _ | |a Khwaja, Omar |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Koerner, Annette |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Hermosilla, Ricardo |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Brugnara, Carlo |0 0000-0001-8192-8713 |b 12 |
| 773 | _ | _ | |a 10.1111/bjh.17479 |g p. bjh.17479 |0 PERI:(DE-600)1475751-5 |n 2 |p 474–481 |t British journal of haematology |v 194 |y 2021 |x 1365-2141 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/893884/files/bjh.17479-2.pdf |
| 856 | 4 | _ | |y Published on 2021-04-30. Available in OpenAccess from 2022-04-30. |u https://juser.fz-juelich.de/record/893884/files/DV-BIT74876_Bito_Thal_Letter%20to%20editor_12March2021_JD.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:893884 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 3 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)177772 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-28 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRIT J HAEMATOL : 2019 |d 2021-01-28 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-28 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-28 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-28 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BRIT J HAEMATOL : 2019 |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-28 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-7-20090406 |k INM-7 |l Gehirn & Verhalten |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-7-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|